1
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Condition(s):Multiple MyelomaLast Updated:July 20, 2021Recruiting
Pembrolizumab: 1656 Clinical Trials, Page 1 of 166
Hide Studies Not Open or Pending
2
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Condition(s):Stage IV Melanoma; Stage III Melanoma; Advanced MelanomaLast Updated:August 19, 2021Active, not recruiting
3
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
Condition(s):HER2-Negative Breast CancerLast Updated:July 21, 2020Recruiting
4
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
Condition(s):Immunotherapy With Pembrolizumab for Nasopharyngeal Carcinoma PatientsLast Updated:March 30, 2021Active, not recruiting
5
Trial of Pembrolizumab in Cancer of Unknown Primary
Condition(s):Cancer of Unknown Primary SiteLast Updated:March 1, 2019Recruiting
6
Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Condition(s):Small Cell Lung CancerLast Updated:February 10, 2020Completed
7
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Condition(s):Ovarian Cancer; Low Grade Serous Carcinoma; Primary Peritoneal Carcinoma; Fallopian Tube CancerLast Updated:September 1, 2021Not yet recruiting
8
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
Condition(s):Cervical CancerLast Updated:June 24, 2021Recruiting
9
Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:August 13, 2021Recruiting
10
Pembrolizumab-PET Imaging
Condition(s):Melanoma; Non-small Cell Lung CancerLast Updated:September 4, 2020Completed